Prevention and monitoring of hepatotoxicity among patients receiving antituberculosis medications

Fei Yuan Hsiao, Yu Hsuan Yen, Chun-Nin Lee, Weng Foung Huang, Hsiang Yin Chen

研究成果: 雜誌貢獻文章

摘要

Antituberculosis therapy frequently causes hepatotoxicity. The study is to evaluate the appropriateness of liver function monitoring during antituberculosis therapy. Two hundred forty five patients treated with antituberculosis agents were included. Abnormal baseline liver function (LFT) was the most significant risk factor for developing hepatotoxicity during the therapy (adjusted OR 23.48; 95%CI: 9.74-56.61). However, the baseline aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were only checked in 76.2% and 75.4% subjects in the hepatotoxic group; and even lower to 58.5% and 57.8% for the non-hepatotoxic group. Although smoking, severe drinking, age, gender and concurrent diseases were significant risk factors, the logistic regression showed that only abnormal baseline LFT (adjusted OR 2.21; 95%CI: 1.22-4.02) and age (adjusted OR 1.02; 95%CI: 1.01-1.04) were determinants of patients receiving follow-up liver function tests (LFTs). Effective strategies to improve the monitoring of liver function should be established to ensure patient safety.
原文英語
頁(從 - 到)107-114
頁數8
期刊Taiwan Pharmaceutical Journal
61
發行號4
出版狀態已發佈 - 十二月 2009

指紋

Liver
Liver Function Tests
Patient Safety
Aspartate Aminotransferases
Alanine Transaminase
Drinking
Therapeutics
Logistic Models
Smoking

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

引用此文

Prevention and monitoring of hepatotoxicity among patients receiving antituberculosis medications. / Hsiao, Fei Yuan; Yen, Yu Hsuan; Lee, Chun-Nin; Huang, Weng Foung; Chen, Hsiang Yin.

於: Taiwan Pharmaceutical Journal, 卷 61, 編號 4, 12.2009, p. 107-114.

研究成果: 雜誌貢獻文章

@article{203a2f0a042b44e7aa49f60da34b14d7,
title = "Prevention and monitoring of hepatotoxicity among patients receiving antituberculosis medications",
abstract = "Antituberculosis therapy frequently causes hepatotoxicity. The study is to evaluate the appropriateness of liver function monitoring during antituberculosis therapy. Two hundred forty five patients treated with antituberculosis agents were included. Abnormal baseline liver function (LFT) was the most significant risk factor for developing hepatotoxicity during the therapy (adjusted OR 23.48; 95{\%}CI: 9.74-56.61). However, the baseline aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were only checked in 76.2{\%} and 75.4{\%} subjects in the hepatotoxic group; and even lower to 58.5{\%} and 57.8{\%} for the non-hepatotoxic group. Although smoking, severe drinking, age, gender and concurrent diseases were significant risk factors, the logistic regression showed that only abnormal baseline LFT (adjusted OR 2.21; 95{\%}CI: 1.22-4.02) and age (adjusted OR 1.02; 95{\%}CI: 1.01-1.04) were determinants of patients receiving follow-up liver function tests (LFTs). Effective strategies to improve the monitoring of liver function should be established to ensure patient safety.",
keywords = "Antituberculosis medications, Hepatotoxicity, Liver function tests",
author = "Hsiao, {Fei Yuan} and Yen, {Yu Hsuan} and Chun-Nin Lee and Huang, {Weng Foung} and Chen, {Hsiang Yin}",
year = "2009",
month = "12",
language = "English",
volume = "61",
pages = "107--114",
journal = "Taiwan Pharmaceutical Journal",
issn = "1016-1015",
publisher = "臺灣藥學會",
number = "4",

}

TY - JOUR

T1 - Prevention and monitoring of hepatotoxicity among patients receiving antituberculosis medications

AU - Hsiao, Fei Yuan

AU - Yen, Yu Hsuan

AU - Lee, Chun-Nin

AU - Huang, Weng Foung

AU - Chen, Hsiang Yin

PY - 2009/12

Y1 - 2009/12

N2 - Antituberculosis therapy frequently causes hepatotoxicity. The study is to evaluate the appropriateness of liver function monitoring during antituberculosis therapy. Two hundred forty five patients treated with antituberculosis agents were included. Abnormal baseline liver function (LFT) was the most significant risk factor for developing hepatotoxicity during the therapy (adjusted OR 23.48; 95%CI: 9.74-56.61). However, the baseline aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were only checked in 76.2% and 75.4% subjects in the hepatotoxic group; and even lower to 58.5% and 57.8% for the non-hepatotoxic group. Although smoking, severe drinking, age, gender and concurrent diseases were significant risk factors, the logistic regression showed that only abnormal baseline LFT (adjusted OR 2.21; 95%CI: 1.22-4.02) and age (adjusted OR 1.02; 95%CI: 1.01-1.04) were determinants of patients receiving follow-up liver function tests (LFTs). Effective strategies to improve the monitoring of liver function should be established to ensure patient safety.

AB - Antituberculosis therapy frequently causes hepatotoxicity. The study is to evaluate the appropriateness of liver function monitoring during antituberculosis therapy. Two hundred forty five patients treated with antituberculosis agents were included. Abnormal baseline liver function (LFT) was the most significant risk factor for developing hepatotoxicity during the therapy (adjusted OR 23.48; 95%CI: 9.74-56.61). However, the baseline aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were only checked in 76.2% and 75.4% subjects in the hepatotoxic group; and even lower to 58.5% and 57.8% for the non-hepatotoxic group. Although smoking, severe drinking, age, gender and concurrent diseases were significant risk factors, the logistic regression showed that only abnormal baseline LFT (adjusted OR 2.21; 95%CI: 1.22-4.02) and age (adjusted OR 1.02; 95%CI: 1.01-1.04) were determinants of patients receiving follow-up liver function tests (LFTs). Effective strategies to improve the monitoring of liver function should be established to ensure patient safety.

KW - Antituberculosis medications

KW - Hepatotoxicity

KW - Liver function tests

UR - http://www.scopus.com/inward/record.url?scp=77954982829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954982829&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77954982829

VL - 61

SP - 107

EP - 114

JO - Taiwan Pharmaceutical Journal

JF - Taiwan Pharmaceutical Journal

SN - 1016-1015

IS - 4

ER -